(Journal Article): Autoimmune Diabetes: Ongoing Development of Immunological Intervention Strategies Targeted Directly Against Autoreactive T Cells
 
Sia C (United Biomedical Inc., 25 Davids Drive, Hauppauge, New York 11788, USA, csia@unitedbiomedical.com )
 
IN: Rev Diabetic Stud 2004; 1(1):9-17
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: It is well known that autoimmunity associated with the onset of insulin-dependent diabetes mellitus (IDDM) involves the generation of autoreactive T and B cells. The findings that diabetics mount humoral and cellular immune responses against islet cell antigens (ICAs) have led to the testing of ICAs and their analogs as candidates for therapeutic agents for better treatment of IDDM at its prediabetic and diabetic stages. Apart from this type of approach, various immunological intervention strategies aimed at direct targeting of the autoreactive T cells have also been investigated. The present review covers the ongoing aspects of these developments focusing on the preclinical findings made in NOD (nonobese diabetic) mice which have been commonly used as a disease model for human autoimmune diabetes. Other types of approaches involving the mobilization of regulatory T cells to indirectly control or modulate the pathological activity of autoreactive T cells will not be discussed within this scope.

TYPE OF PUBLICATION: Review

REFERENCES:

1. Atkinson MA, Maclaren NK, Riley WJ, Winter WE, Fisk DD, Spillar RP. Are insulin autoantibodies markers for insulin-dependent diabetes mellitus? Diabetes 1986. 35:894-898.
2. Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Maclaren NK. Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 1993. 91:350-356.
3. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, Maclaren NK, Notkins AL, Lan MS. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A 1996. 93:2307-2311.
4. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1996. 93: 6367-6370.
5. Gorus FK, Goubert P, Semakula C, Vandewalle CL, De Schepper J, Scheen A, Christie MR, Pipeleers DG. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 1997. 40:95-99.
6. Strebelow M, Schlosser M, Ziegler B, Rjasanowski I, Ziegler M. Karlsburg type I diabetes risk study of a general population: frequencies and interactions of the four major type I diabetes associated autoantibodies studied in 9419 schoolchildren. Diabetologia 1999. 42:661-670.
7. Aanstoot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, Atkinson M, Mose-Larsen P, Fey S, Ludvigsson J, et al. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest 1996. 97:2772-2783.
8. Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998. 47:733-742.
9. Luhder F, Schlosser M, Mauch L, Haubruck H, Rjasanowski I, Michaelis D, Kohnert KD, Ziegler M. Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes. Autoimmunity 1994. 19:71-80.
10. Yu L, Eisenbarth GS. Type 1 diabetes: Molecular, cellular and clinical immunology. www.uchsc.edu/misc/diabetes/ oxch10.html - 67k, last updated Feb 2004.
11. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, Roep BO. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001. 345:1036-1040.
12. Irvine WJ, McCallum CJ, Gray RS, Campbell CJ, Duncan LJ, Farquhar JW, Vaughan H, Morris PJ. Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes 1997. 26:138-147.
13. Riley WJ, Maclaren NK, Krischer J, Spillar RP, Silverstein JH, Schatz DA, Schwartz S, Malone J, Shah S, Vadheim C, et al. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med 1990. 323:1167-1172.
14. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001. 86:3032-3038.
15. Bottazzo GF, Dean BM, McNally JM, Mackay EH, Swift PGF, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetes insulitis. N Engl J Medicine 1985. 313:353-360.
16. Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O. Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992. 90:1901-1910.
17. Itoh N, Hanafusa T, Miyasaki A, Miyagawa J, Yamura S, Inada M, Kawata S, Tarui S, Kono N, Matsuzawa Y. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993. 92:2313-2322.
18. Imagawa A, Hanafusa T, Tamura S, Moriwaki M, Itoh N, Yamamoto K, Iwahashi H, Yamagata K, Waguri M, Nanmo T, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes. Diabetes 2001. 50:1269-1273.
19. Froguel P. Genetics of type 1 insulin-dependent diabetes mellitus. Horm Res 1997 . 48(Suppl 4):55-57.
20. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, Najaran J, Goetz FC. Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type 1 diabetes. Trans Assoc Am Physicians 1984. 97:80-87.
21. Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, Gorsse-Wilde H, Gries FA, Kolb H. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993. 341:1243-1244.
22. Marmont AM. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol 1997. 48(Suppl):13-18.
23. Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C. Genes encoding tumor necrosis factor alpha and Granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci. U S A 1990. 87:2239-2243.
24. Jean-Michel D, Burger D. Cytokines and direct cell contact in synovitis: Relevance to therapeutic intervention. Arthritis Res 1999. 1:17-20.
25. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996. 85:291-297.
26. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: Resolved and unresolved issues. J Clin Invest 2001. 108:1247-1252.
27. Keller RJ. Cellular immunity to human insulin in individuals at high risk for the development of type 1 diabetes mellitus. J Autoimmunity 1994. 3:321-327.
28. Roep BO, Kallan AA, Duinkerken G, Arden SD, Hutton JC, Bruining GJ, de Vries RR. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes 1995. 44:278-283.
29. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetes patients respond to multiple islet cell proteins. J Immunol 1996. 157:5668-5674.
30. Mayer A, Rharbaoui F, Thivolet C, Orgiazzi J, Madec AM. The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in type 1 (insulin-dependent) diabetes mellitus. J Clin Endocrinol Metab 1999. 84:2419-2424.
31. Atkinson MA, Kaufman DL, Campbell L, Gibbs KA, Shah SC, Bu DF, Erlander MG, Tobin AJ, Maclaren NK. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992. 339(8791):458-459.
32. Endl J, Otto H, Jung H, Dreisbusch B, Donie F, Stahr P, Elbracht R, Schmitz G, Mein E, Hummel M, Ziegler AG, Wank R, Schendel DJ. Identification of Naturally Processed T Cell Epitopes from Glutamic Acid Decarboxylase Presented in the Context of HLA-DR Alleles by T Lymphocytes of Recent Onset IDDM Patients. J Clin Invest 1997. 99:2405-2415.
33. Nepom GT, Lippolis JD, White FM, Masewicz S, Marto JA, Herman A, Luckey CJ, Falk B, Shabanowitz J, Hunt DF, Engelhard VH, Nepom BS. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc Natl Acad Sci. U S A 2001. 98:1763-1768.
34. Reijonen H, Novak EJ, Kochik S, Heninger A, Liu AW, Kwok WW, Nepom GT. Detection of GAD65-specific T-Cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002. 51:1375-1382.
35. Panina-Bordignon P, Lang R, van Endert PM, Benazzi E, Felix AM, Pastore RM, Spinas GA, Sinigaglia F. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995. 181:1923-1927.
36. Panagiotopoulos C, Qin H, Tan R, Verchere CB. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes 2003. 52:2647-2651.
37. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990. 39:933-937.
38. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci. U S A 1991. 88:10252-10256.
39. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, tranforming growth factor-beta, and postaglandin-E. Am J Path 1995. 147:1193-1199.
40. Plesner A, Worsaae A, Dyrberg T, Gotfredsen C, Michelsen BK, Pertersen JS. Immunization of diabetes-prone or non-diabetes-prone mcie with GAD65 does not induce diabetes or islet cell pathology. J Autoimmunity 1998. 11:335-341.
41. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type 1 diabetes in high risk, first degree relatives by parental antigen administration: The Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998. 41:536-541.
42. Marks JB. In pursuit of type 1 diabetes prevention. Clinical Diabetes 2002. 20:168-169.
43. Masteller EL, Bluestone JA. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol 2002. 14:652-659.
44. Chase HP, Hayward AR, Eisenbarth GS. Clinical trials for the prevention of type I diabetes. www.uchsc.edu/misc/diabetes/oxch12.html
45. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001. 107:173–180.
46. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994. 24:1853-1857.
47. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996. 93:956-960.
48. Daniel D, Wegmann DR. Intranasal administration of insulin peptide B:9-23 protects NOD mice from diabetes. Proc Natl Acad Sci U S A 1996. 93:956-960.
49. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002. 51:2126-2134.
50. Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, Finkelman FD, Eisenbarth GS. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self peptides B:9-23 and B-13-23. J Clin Invest 2002. 110:1021-1027.
51. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway CA. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999. 5:1026-1031.
52. Hartemann-Heurtier A, Mars LT, Bercovici N, Desbois S, Cambouris C, Piaggio E, Zappulla J, Saoudi A, Liblau RS. An altered self-peptide witrh superagonist activity blocks a CD8 mediated mouse model of type 1 diabetes. J Immunol 2004. 172:915-922.
53. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992. 358(6382):155-157.
54. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993. 366(6450):69-72.
55. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993. 366(6450):72-75.
56. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992. 41:385-391.
57. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987. 165:302-319.
58. Ledletter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch T, Lindsten T, Thompson CB, June CH. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 1990. 75:1531-1539.
59. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000. 12(4):431-440.
60. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene J, Ledletter JA, Singh C, Tepper MA. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992. 257:792-795.
61. Lenschow DJ, Zeng Y, Thistethwaite JR, Montag A, Brady W, Gibson MG, Lindsley PS, Bluestone JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992. 257:789-792.
62. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2002. 19:225-252.
63. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995. 181:1145-1155.
64. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function. J Exp Med 1994. 180:631-640.
65. Ablamunits V, Elias D, Reshef T, Cohen IR. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmunity 1998. 11:73-81.
66. Elias D, Cohen IR. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide. Diabetes 1995. 44:1132-1138.
67. Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, Cohen IR. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997. 46:758-764.
68. Bockova J, Elias D, Cohen IR. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule. J Autoimmunity 1997. 10:323-329.
69. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001. 358:1749-1753.
70. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci. U S A 1994. 91:123-127.
71. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nature Med 2003. 9:1202-1208.
72. Woodle ES, Hussein S, Bluestone JA. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells. Transplantation 1996. 61:798-803.
73. Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA. Phase I evaluation of humanized OKT3: Toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res 1999. 59:2096-2101.
74. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monlconal antibody in new-onset type 1 diabetics mellitus. N Engl J Med 2002. 346:1692-1698.
75. Liu E, Moriyama H, Paronen J, Abiru N, Miao D, Yu L, Taylor RM, Eisenbarth GS. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B9-23 immunization in the NOD mouse. J Autoimmunity 2003. 21:213-219.
76. Phillips JM, Harach SZ, Parish NM, Fehervari Z, Haskins K, Cooke A. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells. J Immunol 2000. 165:1949-1955.
77. Cooke A, Phillips JM, Parish NM. Tolerogenic strategies to halt or prevent type 1 diabetes. Nat Immunol 2001. 2:810-815.
78. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leucocyte emigration. Annu Rev Physiol 1995. 57: 827-872.
79. Hanninen A, Taylor C, Streeter PR, Stark LS, Sarte JM, Shizuru JA, Simell O, Michie SA. Vascular addressins are induced in islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest 1993. 92:2509-2515.
80. Baron JL, Reich EP, Visintin I, Janeway CA. The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest 1994. 93:1700-1708.
81. Kommajosyula S, Reddy S, Nitschke K, Kanwar JR, Karanam M, Krissansen GW. Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy. J Leukoc Biol 2001. 70:510-517.
82. Rosenstein Y, Park JK, Hahn WC, Rosen FS, Bierer BE, Burakoff SJ. CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature 1991. 354:233-235.
83. Johnson GG, Mikulowska A, Butcher EC, McEvoy LM, Michie SA. Anti-CD43 monoclonal antibody L11 blocks migration of T cells to inflamed pancreatic islets and prevents development of diabetes in nonobese diabetic mice. J Immunol 1999. 163:5678-5685.
84. Charlton B, Bacelj A, Mandel TE. Administration of silica particles or anti-Lyt2 antibody prevents beta-cell destruction in NOD mice given cyclophosphamide. Diabetes 1998. 37:930-935.
85. Taki T, Nagata M, Ogawa W, Hatamori N, Hayakawa M, Hari J, Shii K, Baba S, Yokono K. Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody. Diabetes 1991. 40:1203-1209.
86. Mesteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhous N, Bluestone JA. Peptide MHC class II dimmers as therapeutics to modulate antigen-specific T cell response in autoimmune diabetes. J Immunol 2003. 171:5587-5595.